| Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.J Hematol Oncol | PMID 35255929PMC8900437 | 2022-Mar-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.Lancet | PMID 35248186无 PMCID | 2022-Mar-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.N Engl J Med | PMID 35139271PMC8849184 | 2022-Mar-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.N Engl J Med | PMID 35235726无 PMCID | 2022-Mar-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.N Engl J Med | PMID 35235733无 PMCID | 2022-Mar-03 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis.Crit Care | PMID 35241135PMC8892692 | 2022-Mar-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.Inflamm Bowel Dis | PMID 33988236PMC8889281 | 2022-Mar-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.Rheumatology (Oxford) | PMID 34100922无 PMCID | 2022-Mar-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.Crit Care Med | PMID 34612846PMC8855771 | 2022-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.J Clin Oncol | PMID 34709880无 PMCID | 2022-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.Cancer Discov | PMID 34764195PMC8904282 | 2022-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.Cancer | PMID 34878659PMC9299889 | 2022-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.Retina | PMID 34923515无 PMCID | 2022-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.Clin Cancer Res | PMID 34965945PMC9377723 | 2022-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.Vaccine | PMID 35131133PMC8702495 | 2022-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Impact of the Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients: A Randomized Clinical Trial.J Am Coll Surg | PMID 35213496无 PMCID | 2022-Mar-01 | 0.85 | The record describes a randomized Phase III trial in human gastric cancer patients. However, the primary and secondary endpoints (lymph node count, surgical rating, interrupted events) are surgical quality metrics, not survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for inclusion in the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.J Drugs Dermatol | PMID 35254765无 PMCID | 2022-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.JAMA Netw Open | PMID 35353167PMC8969066 | 2022-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.Arthritis Care Res (Hoboken) | PMID 33044756PMC9306696 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.Clin Gastroenterol Hepatol | PMID 33684552无 PMCID | 2022-Mar | 0.95 | The study is a Phase III randomized trial of a drug (tofacitinib) in humans with primary/secondary efficacy and safety results. However, it is not an oncology study; it investigates ulcerative colitis, a non-malignant condition. While the study meets criteria for phase, randomization, drug intervention, and original results, it fails the core requirement of being an oncology (malignant neoplasm) study. | 待处理 |
| Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.Clin Gastroenterol Hepatol | PMID 33838349无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.Clin Gastroenterol Hepatol | PMID 33887475无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial.J Nephrol | PMID 34173940无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.J Nucl Med | PMID 34215673PMC8978200 | 2022-Mar | 0.85 | The study is a randomized Phase II trial focused on optimizing an imaging agent's dosing regimen. It does not report any survival, progression, recurrence, death, or time-to-event efficacy outcomes. | 待处理 |
| Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.J Allergy Clin Immunol | PMID 34403658无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.Mult Scler | PMID 34498507PMC8894682 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.J Allergy Clin Immunol | PMID 34530020无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.J Clin Pharmacol | PMID 34545949PMC9299189 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Duration of estradiol supplementation in luteal phase support for frozen embryo transfer in hormone replacement treatment cycles: a randomized, controlled phase III trial.Arch Gynecol Obstet | PMID 34561715无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A pilot randomized clinical trial of cryopreserved versus liquid-stored platelet transfusion for bleeding in cardiac surgery: The cryopreserved versus liquid platelet-New Zealand pilot trial.Vox Sang | PMID 34581452无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.Ophthalmology | PMID 34597713无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.Br J Cancer | PMID 34621044PMC8854685 | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report.Ophthalmology | PMID 34627809无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.J Geriatr Oncol | PMID 34686472PMC9879719 | 2022-Mar | 0.45 | The record describes an ongoing randomized Phase II/III trial of a drug-containing regimen in oncology, but the abstract does not report any time-to-event efficacy results (e.g., OS, PFS, KM curves, HR). It is a protocol/study description without primary or secondary efficacy outcome data. | 待处理 |
| Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).Br J Dermatol | PMID 34698371无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.Clin Rheumatol | PMID 34709497PMC8873115 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.J Am Acad Dermatol | PMID 34710557无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.Arthritis Rheumatol | PMID 34719872PMC9305108 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.Leukemia | PMID 34725453PMC9014378 | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.Clin Pharmacokinet | PMID 34773606PMC8891099 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.J Eur Acad Dermatol Venereol | PMID 34779063PMC9300205 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.Lancet Infect Dis | PMID 34780705无 PMCID | 2022-Mar | 0.85 | This is a randomized Phase III trial of a quadrivalent HPV vaccine for prevention of genital warts and lesions in men. While it includes anal cancer as a secondary endpoint in MSM, the primary efficacy analysis is based on incidence rates (person-time) for pre-malignant conditions and warts, not on a time-to-event analysis (e.g., Kaplan-Meier, HR) for malignant neoplasm outcomes. The report does not present OS, PFS, DFS, EFS, RFS, or TTP. Therefore, it lacks the required primary/key secondary time-to-event efficacy endpoint for the oncology KM digitization cohort. | 待处理 |
| Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.Clin Pharmacokinet | PMID 34786651PMC8891103 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.Ann Rheum Dis | PMID 34815219PMC8862056 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).Ann Rheum Dis | PMID 34819273PMC8862038 | 2022-Mar | 0.95 | The study is a randomized, controlled Phase IIIb trial of a drug (guselkumab) in humans with psoriatic arthritis, which is not an oncologic malignancy. While it is an original result of a clinical trial, it does not focus on human malignant neoplasms. Furthermore, the primary and key secondary endpoints are based on ACR20, HAQ-DI, SF-36 PCS, and PASI100 (response rates and mean changes), not on time-to-event outcomes like OS, PFS, DFS, or similar survival/metric endpoints typically analyzed with Kaplan-Meier curves or hazard ratios. | 待处理 |
| Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.J Thromb Haemost | PMID 34821020无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.Lancet Infect Dis | PMID 34826381PMC8610426 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study.J Dermatol | PMID 34854112PMC9299697 | 2022-Mar | 0.95 | The study is a randomized, phase 3 clinical trial of a drug intervention (0.75% metronidazole gel) in human patients with original results. However, it is excluded because it is non-oncology (rosacea) and its primary efficacy endpoint is not a time-to-event endpoint (Kaplan-Meier or HR). | 待处理 |
| Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.Ann Oncol | PMID 34861374无 PMCID | 2022-Mar | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.Lancet Respir Med | PMID 34863332PMC8635458 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |